DN

Dileep Namdev

Director Director DIN 06897334
DIN 06897334 First appointment Aug 2014 Primary industry General Business
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 0 active board seats
Past companies 1 historical roles
Total affiliations 1 Since Aug 2014
Shareholding value Locked Premium profile

About Dileep Namdev

Data last updated:

Dileep Namdev has 12 years in corporate governance. Formerly with 1 company, such as Alyssum Pharma Private Limited. Engaged in General Business. Contributes to corporate operations.

DIN 06897334
Primary Designation Director
First Appointment 12 Aug 2014
Oldest Company Age Not Provided

Current companies

No current companies available.

Previous companies

CompanyDesignationAppointmentFoundedStatus
Alyssum Pharma Private Limited U24232MP2014PTC033029
Director12 Aug 20142014Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Alyssum Pharma Private Limited
Premium access

Shareholding and investment profile for Dileep Namdev

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Dileep Namdev

Dileep Namdev has 12 years in corporate governance. Formerly with 1 company, such as Alyssum Pharma Private Limited. Engaged in General Business. Contributes to corporate operations.

Dileep Namdev is associated with 0 companies as a director.

Dileep Namdev has expertise in General Business.

Dileep Namdev has 12 years in corporate governance.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available